REPATHA® (evolocumab)
Repatha® can help you bring your patients LDL-C levels towards the 2019 EAS/ESC targets
Not only does Repatha® substantially reduce LDL-C levels, but these reductions can translate into significant clinical benefits1
Rapid action of LDL-C reduction
A single 140 mg injection maximally suppresses circulating unbound PCSK9 within 4 hours.2 Significant reductions in LDL-C are evident in just 3 weeks.2†
Sustained LDL-C reduction
Significant LDL-C reduction achieved in addition to standard of care; mean LDL-C reduction of 59% achieved at 48 weeks with Repatha® + statin vs placebo+ statin in over 27,000 patients with established CVD.1 Significant reductions sustained for up to 8.4 years.3
Proven CV outcomes in patients with established CVD
Repatha® + statin reduced composite rates of CV death, MI, or stroke in very high-risk patients by 20% vs placebo+ statin.1*
†Repatha® + statin vs placebo+ statin
*This was a key secondary endpoint in the FOURIER trial. The primary endpoint was the relative risk reduction in composite risk of CV death, Ml, stroke, hospitalisation for unstable angina or coronary vascularisation (RR 15%; 1344 events [9.8%] with Repatha® + statin vs 1563 events [11.3%] with placebo+ statin; [ARR 1.5%]). The key secondary endpoint was the relative risk reduction in the composite of CV death, Ml, stroke, (RR 20%; 816 events [5.9%] with Repatha® + statin vs 1,013 events [7.4%] with placebo+ statin; [ARR 1.5%]).
Abbreviations
ARR, absolute risk reduction; CV, cardiovascular; CVD, cardiovascular disease; FH, familial hypercholesterolaemia; HeFH, heterozygous familial hypercholesterolaemia; HoFH, homozygous familial hypercholesterolaemia; LDL-C, low-density lipoprotein cholesterol; Ml, acute myocardial infarction; PCSK9, proprotein convertase subtilisin/kexin type 9; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor.
-
References
- Sabatine MS, et al., N Engl J Med. 2017:376:1713-1722.
- Repatha (evolocumab) Summary of Product Characteristics
- O'Donoghue ML et al., Circulation, 2022:146(15):1109-1119.
GBR-145-0125-80002 | April 2025
-
Adverse Event Reporting InformationAdverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Amgen Limited on +44 (0) 1223 436441.
